MDA-MB-435 human breast carcinoma metastasis to bone

Clinical and Experimental Metastasis

Volumn 20, Issue 4, 2003, Pages 327-334

  Harms, John F ^a   Welch, Danny R ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bone; Breast cancer; Green fluorescent protein; MDA MB 435; Metastasis

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ADRENAL METASTASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FEMUR; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; HUMERUS; INJECTION; LUMBAR VERTEBRA; MANDIBLE; MOUSE; NONHUMAN; OVARY METASTASIS; PROTEIN EXPRESSION; TIBIA; TRABECULAR BONE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; OSTEOLYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0012944342     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024062911144     Document Type: Article

References (44)

1. Ries LAG, Eisner MP, Kosary CL et al. (eds). SEER Cancer Statistics Review, 1973-1999. Bethesda, Maryland: National Cancer Institute 2002.
2. Body JJ. Metastatic bone disease: Clinical and therapeutic aspects. Bone 1992; 13: S57-S62.
3. Duivenvoorden WC, Popovic SV, Lhotak S et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res 2002; 62: 1588-91.
4. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88(12 Suppl): 2892-8.
5. Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551-7.
6. Yoneda T, Williams PJ, Hiraga T et al. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 2001; 16: 1486-95.
7. Yoneda T, Sasaki A, Dunstan C et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509-17.
8. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-405.
9. Yoneda T, Michigami T, Yi B et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 2979-88.
10. Price JE, Zhang RD. Studies of human breast cancer metastasis using nude mice. Cancer Metastasis Rev 1990; 8: 285-97.
11. Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 1997; 15: 272-306.
12. Miller C, Kiriakova G, Su Kim L et al. Characterization of a novel breast cancer cell line established from a bone metastasis. Proc Am Assoc Cancer Res 2002; 43: 316.
13. Thompson EW, Sung V, Lavigne M et al. LCC15-MB: A vimentin-positive human breast cancer cell line from a femoral bone metastasis. Clin Exp Metastasis 1999; 17: 193-204.
14. Sasaki A, Kitamura K, Alcalde RE et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998; 77: 279-85.
15. Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002; 20: 299-303.
16. Wang CY, Chang YW. A model for osseous metastasis of human breast cancer established by intrafemur injection of the MDA-MB-435 cells in nude mice. Anticancer Res 1997; 17: 2471-4.
17. Thomas RJ, Guise TA, Yin JJ et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-8.
18. Peyruchaud O, Winding B, Pecheur I et al. Early detection of bone metastases in a routine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001; 16: 2027-34.
19. Averbuch SD. New bisphosphonates in the treatment of bone metastases. Cancer 1993; 72: 3443-52.
20. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48: 6876-81.
21. Holleran JL, Miller CJ, Edgehouse NL et al. Differential experimental micrometastasis to lung, liver, and bone with lacZ-tagged CWR22R prostate carcinoma cells. Clin Exp Metastasis 2002; 19: 17-24.
22. Lin WC, Pretlow TP, Pretlow TG et al. Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression. Cancer Res 1990; 50: 2808-17.
23. Culp LA, Lin WC, Kleinman NR. Tagged tumor cells reveal regulatory steps during earliest stages of tumor progression and micrometastasis. Histol Histopathol 1999; 14: 879-86.
24. Wetterwald A, van der PG, Que I et al. Optical imaging of cancer metastasis to bone marrow: A mouse model of minimal residual disease. Am J Pathol 2002; 160: 1143-53.
25. Goldberg SF, Harms JF, Quon K et al. Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate. Clin Exp Metastasis 1999; 17: 601-7.
26. Hoffman RM. Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer Metastasis Rev 1998; 17: 271-7.
27. Naumov GN, Wilson SM, MacDonald IC et al. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci 1999; 112: 1835-42.
28. Yang M, Jiang P, An Z et al. Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 1999; 5: 3549-59.
29. Yang M, Jiang P, Sun FX et al. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res 1999; 59: 781-6.
30. Cook MJ. The Anatomy of the Laboratory Mouse. New York: Academic Press 1965.
31. Price JE, Polyzos A, Zhang RD et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-21.
32. Hoffman RM. Visualization of GFP-expressing tumors and metastasis in vivo. Biotechniques 2001; 30: 1016-26.
33. Al Mehdi AB, Tozawa K, Fisher AB et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: A new model for metastasis. Nat Med 2000; 6: 100-2.
34. Naumov GN, MacDonald IC, Weinmeister PM et al. Persistence of solitary mammary carcinoma cells in a secondary site: A possible contributor to dormancy. Cancer Res 2002; 62: 2162-8.
35. Lote K, Walloe A, Bjersand A. Bone metastasis. Prognosis, diagnosis and treatment. Acta Radiol Oncol 1986; 25: 227-32.
36. Miller F, Whitehill R. Carcinoma of the breast metastatic to the skeleton. Clin Orthop 1984; 184: 121-7.
37. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991; 9: 509-24.
38. Mbalaviele G, Dunstan CR, Sasaki A et al. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996; 56: 4063-70.
39. Sasaki A, Alcalde RE, Nishiyama A et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998; 58: 462-7.
40. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204-15.
41. Sasaki A, Yoneda T, Terakado N et al. Experimental bone metastasis model of the oral and maxillofacial region. Anticancer Res 1998; 18: 1579-84.
42. Sasaki A, Nishiyama A, Alcalde RE et al. Effects of bisphosphonate on experimental jaw metastasis model in nude mice. Oral Oncol 1999; 35: 523-9.
43. Yang M, Hasegawa S, Jiang P et al. Widespread skeletal metastatic potential of human lung cancer revealed by green fluorescent protein expression. Cancer Res 1998; 58: 4217-21.
44. Harms JF, Budgeon LR, Christensen ND et al. Maintaining GFP tissue fluorescence through bone decalcification and long-term storage. Biotechniques 2002; 33: 1197-200.